Details for New Drug Application (NDA): 074961
✉ Email this page to a colleague
NDA 074961 describes CIMETIDINE, which is a drug marketed by Apotex, Chartwell Molecules, Chartwell Rx, Contract Pharmacal, Cycle, Hikma, Ivax Sub Teva Pharms, L Perrigo Co, Mylan, Novitium Pharma, Perrigo, Pliva, Sandoz, Teva, Upsher Smith Labs, Watson Labs Inc, Watson Labs Teva, Cosette, Endo Operations, Hospira, Luitpold, Teva Parenteral, Ani Pharms, Chartwell Molecular, G And W Labs Inc, Pai Holdings Pharm, Pharm Assoc, and Pharmobedient Cnsltg, and is included in forty-nine NDAs. It is available from sixteen suppliers. Additional details are available on the CIMETIDINE profile page.
The generic ingredient in CIMETIDINE is cimetidine hydrochloride. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cimetidine hydrochloride profile page.
The generic ingredient in CIMETIDINE is cimetidine hydrochloride. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cimetidine hydrochloride profile page.
Summary for 074961
| Tradename: | CIMETIDINE |
| Applicant: | Contract Pharmacal |
| Ingredient: | cimetidine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 074961
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Jun 19, 1998 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
